KR20240101555A - 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도 - Google Patents

사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240101555A
KR20240101555A KR1020247012612A KR20247012612A KR20240101555A KR 20240101555 A KR20240101555 A KR 20240101555A KR 1020247012612 A KR1020247012612 A KR 1020247012612A KR 20247012612 A KR20247012612 A KR 20247012612A KR 20240101555 A KR20240101555 A KR 20240101555A
Authority
KR
South Korea
Prior art keywords
alkyl
solvate
tautomer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247012612A
Other languages
English (en)
Korean (ko)
Inventor
앤서니 비 핑커턴
자크 마우거
옌 팜 홍 트루옹
레이첼 자네트 엘스돈
스티븐 토드 마이어
Original Assignee
바운드리스 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바운드리스 바이오, 인크. filed Critical 바운드리스 바이오, 인크.
Publication of KR20240101555A publication Critical patent/KR20240101555A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247012612A 2021-09-17 2022-09-15 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도 Pending KR20240101555A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
US63/245,718 2021-09-17
PCT/US2022/043660 WO2023043923A1 (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20240101555A true KR20240101555A (ko) 2024-07-02

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247012612A Pending KR20240101555A (ko) 2021-09-17 2022-09-15 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도

Country Status (11)

Country Link
US (1) US20250002486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534420A (cg-RX-API-DMAC7.html)
KR (1) KR20240101555A (cg-RX-API-DMAC7.html)
CN (1) CN118434417A (cg-RX-API-DMAC7.html)
AU (1) AU2022345092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231660A1 (cg-RX-API-DMAC7.html)
IL (1) IL311458A (cg-RX-API-DMAC7.html)
MX (1) MX2024003258A (cg-RX-API-DMAC7.html)
TW (1) TW202328121A (cg-RX-API-DMAC7.html)
WO (1) WO2023043923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4587437A1 (en) * 2022-09-13 2025-07-23 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2594799A (en) * 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
ES2982299T3 (es) * 2016-05-31 2024-10-15 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida o sal de los mismos como inhibidores de ribonucleótido reductasa para el tratamiento del cáncer
TWI748142B (zh) * 2017-11-29 2021-12-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑
AU2018377036B2 (en) * 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
MA56065A (fr) * 2019-05-29 2022-04-06 Taiho Pharmaceutical Co Ltd Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur
EP4301735A4 (en) * 2021-03-02 2025-05-21 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Also Published As

Publication number Publication date
MX2024003258A (es) 2024-04-05
EP4401728A1 (en) 2024-07-24
IL311458A (en) 2024-05-01
US20250002486A1 (en) 2025-01-02
WO2023043923A1 (en) 2023-03-23
JP2024534420A (ja) 2024-09-20
CA3231660A1 (en) 2023-03-23
EP4401728A4 (en) 2025-08-06
TW202328121A (zh) 2023-07-16
CN118434417A (zh) 2024-08-02
AU2022345092A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US11707462B2 (en) Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
JP2025522294A (ja) ピリジンチェックポイントキナーゼ1(chk1)阻害剤及びその使用
WO2024118564A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
EA021126B1 (ru) Замещенные изохинолиноны и хинализолиноны
BRPI0610876B1 (pt) composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20250002486A1 (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EA019973B1 (ru) ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ
TW201004940A (en) Heteroaryl compounds and uses thereof
US20200405697A1 (en) Antitumor Agent
JP6713000B2 (ja) 抗腫瘍活性を有する化合物
US20240158383A1 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
WO2023043938A1 (en) Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2025531147A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
EA051928B1 (ru) Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение
TW201127837A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240416

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application